Replies to post #427169 on Anavex Life Sciences Corp (AVXL)

[abew4me]

I wholeheartedly disagree.

Once A2-73 is approved for Rett, Anavex will be conducting numerous P3 trials for other rare diseases...especially Fragile X. If the P3 trial for Fragile X is successful, Anavex will most certainly repurpose A2-73 and submit an NDA - immediately!

The same scenario will be executed for Alzheimer's Disease if the FDA agrees that our n=509 P2b/3 and the OLE (along with all of the other P1 and P2 results) are a large enough package to qualify for a drug repurposing NDA.

IMO, this has always been the game plan that Dr. Missling was going to execute.

One thing is for sure, Anavex has filed dozens of patents for neurological diseases that A2-73 can be used for...and I guarantee that our pipeline is going to explode once A2-73 is approved for Rett.

Just sit back and enjoy the ride folks. The second half of 2023 is just the beginning of a long line of successes that we'll experience.

Cheers.